<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">101485158</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">36319</journal-id>
      <journal-id journal-id-type="nlm-ta">Immunotherapy</journal-id>
      <journal-id journal-id-type="iso-abbrev">Immunotherapy</journal-id>
      <journal-title-group>
        <journal-title>Immunotherapy</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1750-743X</issn>
      <issn pub-type="epub">1750-7448</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23413907</article-id>
      <article-id pub-id-type="pmc">4086484</article-id>
      <article-id pub-id-type="doi">10.2217/imt.12.155</article-id>
      <article-id pub-id-type="manuscript">NIHMS585831</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Vaccine strategies for glioblastoma: progress and future directions</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Jackson</surname>
            <given-names>Christopher</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN2" ref-type="author-notes">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ruzevick</surname>
            <given-names>Jacob</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN2" ref-type="author-notes">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brem</surname>
            <given-names>Henry</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lim</surname>
            <given-names>Michael</given-names>
          </name>
          <xref rid="FN1" ref-type="author-notes">*</xref>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN2" ref-type="author-notes">&#x2021;</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>The Johns Hopkins Hospital, Department of Neurosurgery, Phipps Building, Room 123, 600 North Wolfe Street, Baltimore, MD 21287, USA</aff>
      <author-notes>
        <corresp id="FN1"><label>*</label>Author for correspondence: Tel.: +1 410 614 1627, Fax: +1 410 502 4954, <email>mlim3@jhmi.edu</email></corresp>
        <fn id="FN2" fn-type="equal">
          <label>&#x2021;</label>
          <p>Authors contributed equally</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>20</day>
        <month>5</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>08</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>5</volume>
      <issue>2</issue>
      <fpage>155</fpage>
      <lpage>167</lpage>
      <!--elocation-id from pubmed: 10.2217/imt.12.155-->
      <permissions>
        <copyright-statement>&#xA9; 2013 Future Medicine Ltd</copyright-statement>
        <copyright-year>2013</copyright-year>
      </permissions>
      <abstract>
        <p id="P1">Recent advances in glioblastoma therapy have led to optimism that more effective therapies will improve outcomes. Immunotherapy is a promising approach that has demonstrated the potential to eradicate cancer cells with cellular-level accuracy while minimizing damage to surrounding healthy tissue. Several vaccination strategies have been evaluated for activity against glioblastoma in clinical trials. These include peptide vaccines, polyvalent dendritic cell vaccines, heat shock protein vaccines and adoptive immunotherapy. In this review, we highlight clinical trials representative of each of these approaches and discuss strategies for integrating these therapies into routine patient care.</p>
      </abstract>
      <kwd-group>
        <kwd>chemotherapy</kwd>
        <kwd>glioblastoma</kwd>
        <kwd>immunotherapy</kwd>
        <kwd>radiation therapy</kwd>
        <kwd>tumor-associated antigen</kwd>
        <kwd>vaccine</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
</pmc-articleset>